Electrical stimulation therapy may have a big impact on brain health and recovery in patients with mood disorders, dementia and neurodegenerative disorders.
Pacific Neuroscience Institute, the leading enrollment site for the MDNA55 clinical trial for Glioblastoma, is still open and enrolling eligible patients. This innovative phase 2 study is for the minimally invasive convection-enhanced delivery (CED) of a new bioengineered targeted therapeutic, MDNA55, in adults with recurrent or progressive glioblastoma. Read more.
Pacific Neuroscience Institute opens up two new clinical trials this month, one in Essential Tremor and one in Glioblastoma. Find out more about these new trials as well as the other available open neurological studies.
The Pacific Movement Disorders Center team is excited to announce that we are one of the sites participating in the PROSPECT trial from Cala Health, a three month study for people who have mild to severe essential tremor. The trial is open for patient enrollment.
Find out about the latest clinical trials at Pacific Neuroscience Institute for brain tumor, stroke, movement disorders, and other neurological areas. Call our center at 310-829-8265 to enroll.
Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM). Data suggest the Nativis Voyager® device is safe for treatment of rGBM.
Dr. Sarah McEwen’s determination to make a difference bridges the gap between academic research and the underserved populations in the community. Her research and clinical work implement physical and cognitive interventions simultaneously during the earliest phases of illness with the possibility of preventing cognitive decline. Read more.
Find out about the latest clinical trials at Pacific Neuroscience Institute for brain tumor, stroke and other neurological areas. Call our center at 310-829-8265 to enroll.
The EndBrainCancer Initiative Receives CITI Certification Becoming the First Brain Tumor Patient Advocacy Organization Listed as a Nationally-Recognized Recruiting Site.
The Wizard201G clinical trial from Boston Biomedical Inc. is a vaccine treatment for patients with recurrent or progressive GBM following initial treatment. Pacific Neuroscience Institute is a site for this phase 2 study which is currently recruiting. Contact us for eligibility criteria at 310-582-7460.